Great Point Partners LLC Portfolio Holdings

Great Point Partners LLC

  • $216 Million
  • Q3 2024

Great Point Partners LLC has filed its 13F form on November 13, 2024 for Q3 2024 where it was disclosed a total value porftolio of $216 Million distributed in 30 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Pliant Therapeutics, Inc. with a value of $21.4M, Evolus, Inc. with a value of $19M, Viridian Therapeutics, Inc.\De with a value of $17.1M, Cytokinetics Inc with a value of $16.7M, and Kal Vista Pharmaceuticals, Inc. with a value of $15M.

Examining the 13F form we can see an decrease of $161M in the current position value, from $377M to 216M.

Great Point Partners LLC is based out at Greenwich, CT

Below you can find more details about Great Point Partners LLC portfolio as well as his latest detailed transactions.

Portfolio value $216 Million
Healthcare: $213 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$660M
$21.4 Million 9.9% of portfolio
1,910,121
Q3 2024 Reduced 27.56%
$622M
$19 Million 8.76% of portfolio
1,170,000
Q3 2024 Reduced 52.28%
$776M
$17.1 Million 7.89% of portfolio
750,000
Q3 2024 Added 50.0%
$4.46B
$16.7 Million 7.71% of portfolio
316,000
Q3 2024 Reduced 33.36%
$210M
$15 Million 6.96% of portfolio
1,299,503
Q3 2024 Reduced 2.92%
$1.64B
$14.8 Million 6.83% of portfolio
1,326,234
Q3 2024 Reduced 44.14%
$17.6M
$13.6 Million 6.28% of portfolio
6,934,982
Q3 2024 Reduced 6.53%
$1.93B
$12.5 Million 5.78% of portfolio
250,000
Q3 2024 Reduced 52.23%
$249M
$11.9 Million 5.52% of portfolio
1,000,000
Q3 2024 Added 25.49%
$5.1B
$10.2 Million 4.72% of portfolio
255,000
Q3 2024 Reduced 22.73%
$205M
$10.2 Million 4.72% of portfolio
2,811,955
Q3 2024 Reduced 18.3%
$245M
$9.64 Million 4.46% of portfolio
758,786
Q3 2024 Reduced 73.89%
$32.5M
$8.62 Million 3.98% of portfolio
12,861,136
Q3 2024 Reduced 6.31%
$3.47B
$8.35 Million 3.86% of portfolio
100,000
Q3 2024 Reduced 79.67%
$222M
$5.62 Million 2.6% of portfolio
959,953
Q3 2024 Reduced 40.06%
$57.9M
$5.06 Million 2.34% of portfolio
1,016,375
Q3 2024 Added 8.03%
$0
$3.49 Million 1.61% of portfolio
2,790,698
Q3 2024 New
$109M
$1.26 Million 0.58% of portfolio
248,168
Q3 2024 New
Vistagen Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 55.92%
Outlook Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 24.01%
Oruka Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Neurogene Inc
-
$0 0.0% of portfolio
-
Q1 2024 Added 1.01%
Abivax Sa
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 13.89%
Jasper Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 19.81%
Helix Acquisition Corp Ii
-
$0 0.0% of portfolio
-
Q1 2024 New
Dianthus Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 63.72%
Cartesian Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Zura Bio LTD
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 29.7%

Summary

  • Portfolio
  • No. of Stocks 30
  • Current Value $216 Million
  • Prior Value $377 Million
  • Filing
  • Period Q3 2024
  • Filing Date November 13, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 5 stocks
  • Additional Purchases 3 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 19 stocks
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email